A new rapid-acting inhaled insulin, Afrezza, has been introduced in India, offering an alternative for patients hesitant about insulin injections. This development aims to address 'insulin inertia,' a common reason for delaying or avoiding necessary insulin therapy due to fear of needles or inconvenience. Experts suggest inhaled insulin could improve patient comfort, confidence, and adherence to treatment, particularly for those managing diabetes with multiple daily injections.